Journal ArticleDOI
Reviewing the role of emerging therapies in the ADHD armamentarium.
Reads0
Chats0
TLDR
A robust pipeline of stimulants and nonstimulants in development are found, formulated to optimize onset and duration of effect, alter the time of administration, obviate the need to swallow whole capsules or tablets and to deter abuse.Abstract:
Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder that can be treated with both pharmacologic and nonpharmacologic modalities. Effective drug treatm...read more
Citations
More filters
Meta-analysis of organizational skills interventions for children and adolescents with Attention-Deficti/Hyperactivity Disorder
TL;DR: In this article, the authors conducted a systematic review and meta-analysis of OST in children with ADHD and found that OST leads to moderate improvements in organizational skills as rated by teachers and large improvements by parents, while more modest improvements were observed on the ratings of symptoms of inattention and academic performance.
Journal ArticleDOI
Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder.
TL;DR: A review of FDA approved and emerging medication options while providing guidelines for pharmacologic management of adult ADHD is presented in this paper . But, limitations still persist in available psychotropics for certain patient populations such as those with comorbid substance use or cardiovascular illness.
Journal ArticleDOI
111 Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301) Assessing Efficacy and Safety of Extended-Release Viloxazine in Children with ADHD
TL;DR: In this study, SPN-812 at 100 mg and 200 mg doses met the primary and secondary objectives with statistical significance and was well tolerated in children ages 6-11yrs with ADHD.
References
More filters
Journal ArticleDOI
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
Timothy Wigal,Jeffrey H. Newcorn,Nelson Handal,Sharon B. Wigal,Ioulietta Mulligan,Virginia D. Schmith,Eric Konofal +6 more
TL;DR: Overall, mazindol CR had minimal effects on blood pressure and small effects on HR, and was well tolerated, supporting the progression to phase III.
Journal ArticleDOI
Effects of mazindol in two patients with Prader-Willi syndrome
TL;DR: In this paper, two patients with Prader-Willi syndrome, including gross obesity with food-related behavior and mild mental retardation, were treated with mazindol in one or two daily doses.
Journal ArticleDOI
Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder
Eric Konofal,Wei Zhao,Cédric Laouénan,Michel Lecendreux,Florentia Kaguelidou,L. Benadjaoud,Evelyne Jacqz-Aigrain +6 more
TL;DR: This preliminary study shows that mazindol might be an effective, well-tolerated, and long-acting (more than 8 hours) agent for the treatment of ADHD in children.
Journal ArticleDOI
Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
Sara Dehbozorghi,Sayna Bagheri,Kamyar Moradi,Kamyar Shokraee,Mohammad Reza Mohammadi,Shahin Akhondzadeh +5 more
TL;DR: This study evaluated the efficacy and safety of tipepidine as an add‐on to methylphenidate in the drug treatment of attention‐deficit/hyperactivity disorder (ADHD).
Journal ArticleDOI
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Tobias Banaschewski,Mats Johnson,Peter L. Nagy,Isabel Hernández Otero,Cesar Soutullo,Brian Yan,Alessandro Zuddas,David Coghill,David Coghill +8 more
TL;DR: Findings from this comprehensive examination of growth outcomes associated with lisdexamfetamine dimesylate treatment over 2 years were consistent with previous studies of stimulant medications.